SAM
IKT icon

Synergy Asset Management’s Inhibikase Therapeutics IKT Stock Holding History

Synergy Asset Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50
Closed -$65 – 435
2024
Q4 		$65 Buy
+50
New +$125 ﹤0.01% 847

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Synergy Asset Management's IKT Position: Q1 2025 in Review

Synergy Asset Management sold out of Inhibikase Therapeutics (IKT) in Q1 2025, closing a stake of 50 shares — an estimated $65 sold.

Synergy Asset Management first reported a position in IKT in Q4 2024 and held it in 1 quarter. The position peaked at $65 in Q4 2024. 47 funds tracked by Wall St. Rank hold IKT as of Q1 2025.

  • Synergy Asset Management reported no remaining Inhibikase Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Synergy Asset Management sold 50 Inhibikase Therapeutics shares in Q1 2025, an estimated $65.
  • Synergy Asset Management first reported a position in Inhibikase Therapeutics in Q4 2024 and held it in 1 quarter.
  • Synergy Asset Management's Inhibikase Therapeutics position peaked at $65 in Q4 2024.
  • 47 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2025.

Based on Synergy Asset Management's 13F filing for Q1 2025, filed 22 Apr 2025.